Literature DB >> 18997570

Selective serotonin reuptake inhibitors (SSRIs) in pregnancy: a review.

Robin Fleschler1, Melissa F Peskin.   

Abstract

Major affective disorders including depression and anxiety occur commonly in women of childbearing age and their incidence can increase during and after pregnancy. There is a critical clinical demand for treatment of these disorders, but the balance between treating affective disorders without harming the developing fetus is a difficult one. This has created concern both among women planning pregnancies, and those women who are pregnant already, as well as among families and healthcare providers. Currently, selective serotonin reuptake inhibitors (SSRIs) are the drugs of choice for the treatment of these disorders in pregnant women because of their documented efficacy and mild side effect profile. There is some research concerning SSRI use and pregnancy, which is the focus of this article.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997570     DOI: 10.1097/01.NMC.0000341255.80426.7b

Source DB:  PubMed          Journal:  MCN Am J Matern Child Nurs        ISSN: 0361-929X            Impact factor:   1.412


  6 in total

1.  Comparison of the function of the serotonin transporter in the vasculature of male and female rats.

Authors:  Aurea Elizabeth Linder; Robert Patrick Davis; Robert Burnett; Stephanie W Watts
Journal:  Clin Exp Pharmacol Physiol       Date:  2011-05       Impact factor: 2.557

2.  Developmental fluoxetine exposure facilitates sexual behavior in female offspring.

Authors:  Ine Rayen; Harry W M Steinbusch; Thierry D Charlier; Jodi L Pawluski
Journal:  Psychopharmacology (Berl)       Date:  2013-07-31       Impact factor: 4.530

3.  Fluoxetine induces lean phenotype in rat by increasing the brown/white adipose tissue ratio and UCP1 expression.

Authors:  A I da Silva; G R F Braz; A A Pedroza; L Nascimento; C M Freitas; D J S Ferreira; R Manhães de Castro; C J Lagranha
Journal:  J Bioenerg Biomembr       Date:  2015-07-01       Impact factor: 2.945

4.  Developmental exposure to SSRIs, in addition to maternal stress, has long-term sex-dependent effects on hippocampal plasticity.

Authors:  Ine Rayen; Mary Gemmel; Grace Pauley; Harry W M Steinbusch; Jodi L Pawluski
Journal:  Psychopharmacology (Berl)       Date:  2014-10-12       Impact factor: 4.530

5.  An ecological study on childhood autism.

Authors:  Sophie St-Hilaire; Victor O Ezike; Henrik Stryhn; Michael A Thomas
Journal:  Int J Health Geogr       Date:  2012-10-11       Impact factor: 3.918

6.  Fluoxetine during development reverses the effects of prenatal stress on depressive-like behavior and hippocampal neurogenesis in adolescence.

Authors:  Ine Rayen; Daniël L van den Hove; Jos Prickaerts; Harry W Steinbusch; Jodi L Pawluski
Journal:  PLoS One       Date:  2011-09-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.